در هنگام جستجو کلمه در قسمت عنوان میتوانید کلمات مورد جستجو را با کاراکتر (-) جدا کنید.
کاربرد نوع شرط:
- جایگاه : پژوهشی
- مجله: Asian Pacific Journal of Cancer Prevention
- نوع مقاله: Journal Article
- کلمات کلیدی: toxicity,Modified DCF,survival rate,Advanced gastric adenocarcinoma,FOLFOX
- چکیده:
- چکیده انگلیسی: Objectives: Chemotherapy is used as an indispensable therapy for advanced gastric cancer. Different chemotherapy regimens have been used for this purpose. Toxicity due to the Chemotherapy drugs is one limiting factor. In this study we aim to compare the efficacy and toxicity of two regimens FOLFOX (leucoverin, 5-fluorouracil and oxaliplatin) and modified DCF (mDCF) (docetaxel, cisplatin, and 5-fluorouracil) in patients with advanced gastric adenocarcinoma. Methods: In this analytical cross-sectional study, 47 patients treated with FOLFOX regimen and 57 patients treated with mDCF regimen were recruited, Patients in both groups were compared for demographic findings, response rate, mortality rate, overall survival (OS) and progression free survival (PFS). Results: In FOLFOX and mDCF group, complete response (CR) occurred in 4.3% and 5.3%, partial response (PR) in 42.6% and 29.8%, stable disease in 34% and 52.6% and disease progression in 19.1% and 12.3%, respectively (p=0.25). Overall response rate was 48.9% and 56.1%, respectively. There was no significant difference between two regimens in OS and PFS (p=0.22). mDCF compared to FOLFOX had significantly higher hematologic, gastrointestinal complications, as well as creatinine rise, stomatitis and hair loss, but peripheral neuropathy was significantly lower. Conclusion: The results of current study showed that in patients with advanced gastric adenocarcinoma, FOLFOX regimen compared to mDCF regimen have similar ORR, OS and PFS. Toxicity rate are also lower in FOLFOX group, thus it seems a better regimen for chemotherapy.
- انتشار مقاله: 16-02-1399
- نویسندگان: Mehdi Pourghasemian,Amin Danandeh Mehr,Mohammad Molaei,Afshin Habibzadeh
- مشاهده
- جایگاه : پژوهشی
- مجله: Asian Pacific Journal of Cancer Prevention
- نوع مقاله: Journal Article
- کلمات کلیدی: Bone Marrow Transplantation,Prophylaxis,Fungal infection
- چکیده:
- چکیده انگلیسی: Objective: Invasive fungal infections (IFI) in bone marrow transplant (BMT) recipients are common and lethal.
Fluconazole was the choice prophylaxis previously, but recent strategy utilization antifungal drugs according to the risk
of IFI in patients undergoing transplantation. In this study we aim to evaluate the efficacy of fluconazole prophylaxis
regimen and the regimes chosen by the patient’s risk of IFI. Materials and Methods: We evaluated 376 patients with
BMT. Patients were divided into those treated before 2012 with fluconazole prophylaxis (group I, n=206) or those
undergone transplantation after 2012 and received fluconazole, voriconazole and posaconazole prophylaxis according
their risk of fungal infection (group II, n=170). Results: Group I was significantly younger (p=0.007), less smoker
(p=0.01), received more autologus transplant (p=0.001) and mostly high risk patient for infection (p<0.001). Group
I had significantly higher duration of fever (p=0.004) and increased WBC (p=0.02), longer length of stay (p=0.001),
more proven and less probable fungal infections (p=0.008) and higher hepatic complications (p=0.003). There was no
significant difference in fungal related and overall mortality rate between groups. Conclusion: The use of prophylaxis
based on risk of fungal infection in patients undergoing BMT results in reduce fungal infections, duration of fever and
accelerate the engraftment and patient discharge.- انتشار مقاله: 28-10-1396
- نویسندگان: Mehdi Pourghasemian,Mahshid Mehdizadeh,Abbas Hajfathali,Afshin Habibzadeh,Mohammad Hossein Hosseinin
- مشاهده